DDX3X Induces Primary EGFR-TKI Resistance Based on Intratumor Heterogeneity in Lung Cancer Cells Harboring EGFR-Activating Mutations - Figure 4

A. Immunoblotting analysis of EGFR, phospho-EGFR (Tyr1068), and DDX3X in cancer cells without EGF supplementation. B. Immunoblotting analysis of phospho-EGFR at Tyr1068, Tyr1173, and Tyr845 in parental PC9 cells and A-1 cells. C. Kinetic analysis of EGFR signaling in parental PC9 cells and A-1 cells. EGFR, phospho-EGFR (Tyr1068), Akt, phospho-Akt, ERK1/2, and phospho-ERK1/2 levels were analyzed by immunoblotting at 0, 15, 30, 60, 120, and 900 min after the addition of 100 ng/mL EGF.